CoChat
Sign Up
Cited by 87

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

PD-1/PD-L1 immune-checkpoint inhibitors in glioblastoma: A concise review

Caccese, Mario, Indraccolo, Stefano, Zagonel, Vittorina, Lombardi, Giuseppe·2019·Critical Reviews in Oncology/Hematology
DOI 10.1016/j.critrevonc.2018.12.002
Open this paper in CoChat — free account

Abstract

Glioblastoma is the most aggressive and most common primary brain tumor in adults, with a very poor prognosis, due to limited therapeutic efficacy of available treatments. The promising data deriving from the use of immune checkpoint inhibitors (ICI) in other cancers have prompted evaluation of its efficacy and possible use in patients with glioblastoma. In this review, we analyzed the available data about these drugs in glioblastoma. Although data are not yet mature and preliminary studies do not show a clear-cut benefit, we are far from excluding the concrete possibility of using ICI as potential treatment in patients with glioblastoma. Moreover, many molecular and immunological aspects of this approach have yet to be clarified. For this reason, it is essential to identify potential predictive biomarkers for the selection of patients who will benefit most from treatment with ICI. Additional effort is needed to better understand the mechanisms that will allow us to establish whether ICI have a place in the treatment of patients with glioblastoma.

Overview

Integrity signals

Registry

Crossref · 10.1016/j.critrevonc.2018.12.002

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 5 references

Research works printed but not linked: 61

  1. Ansell, 2015, PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma, N. Engl. J. Med., 372, 311, 10.1056/NEJMoa1411087 · DOI
  2. Atkins, 2014, Phase 2, multicenter, safety and efficacy study of pidilizumab in patients with metastatic melanoma, J. Clin. Oncol., 32
  3. Banks, 2009, Characteristics of compounds that cross the blood-brain barrier, BMC Neurol., 9
  4. Berghoff, 2016, In search of a target: PD-1 and PD-L1 profiling across glioma types, Neuro Oncol., 18, 1331, 10.1093/neuonc/now162 · DOI
  5. Berghoff, 2015, Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma, Neuro Oncol., 17, 1064, 10.1093/neuonc/nou307 · DOI
  6. Berghoff, 2017, Correlation of immune phenotype with IDH mutation in diffuse glioma, Neuro Oncol., 19, 1460, 10.1093/neuonc/nox054 · DOI
  7. Bouffet, 2016, Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency, J. Clin. Oncol., 34, 2206, 10.1200/JCO.2016.66.6552 · DOI · Paper page
  8. Brahmer, 2010, Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates, J. Clin. Oncol., 28, 3167, 10.1200/JCO.2009.26.7609 · DOI
  9. Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N. Engl. J. Med., 373, 123, 10.1056/NEJMoa1504627 · DOI · Paper page
  10. Cahill, 2007, Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment, Clin. Cancer Res., 13, 2038, 10.1158/1078-0432.CCR-06-2149 · DOI
  11. Cancer Genome Atlas Research Network, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 · DOI · Paper page
  12. Chamberlain, 2015, Salvage therapy with lomustine for temozolomide refractory recurrent anaplastic astrocytoma: a retrospective study, J. Neurooncol., 122, 329, 10.1007/s11060-014-1714-9 · DOI
  13. Chamberlain, 2010, Salvage therapy with single agent bevacizumab for recurrent glioblastoma, J. Neurooncol., 96, 259, 10.1007/s11060-009-9957-6 · DOI
  14. Chamberlain, 2017, Nivolumab for patients with recurrent glioblastoma progressing on bevacizumab: a retrospective case series, J. Neurooncol., 133, 561, 10.1007/s11060-017-2466-0 · DOI
  15. Champiat, 2014, Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy, Oncoimmunology, 3, 10.4161/onci.27817 · DOI
  16. Chan, 2015, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 373, 1984, 10.1056/NEJMc1508163 · DOI
  17. Chen, 2015, Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future, J. Clin. Invest., 125, 3384, 10.1172/JCI80011 · DOI
  18. Chen, 2012, Modern methods for delivery of drugs across the blood-brain barrier, Adv Drug Deliv. Rev., 64, 640, 10.1016/j.addr.2011.11.010 · DOI
  19. Curran, 2010, PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors, Proc. Natl. Acad. Sci. U. S. A., 107, 4275, 10.1073/pnas.0915174107 · DOI · Paper page
  20. De Groot, 2018, Window-of-opportunity clinical trial of a PD-1 inhibitor in patients with recurrent glioblastoma, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.2008 · DOI
  21. Dix, 1999, Immune defects observed in patients with primary malignant brain tumors, J. Neuroimmunol., 100, 216, 10.1016/S0165-5728(99)00203-9 · DOI
  22. Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J. Clin. Oncol., 27, 4733, 10.1200/JCO.2008.19.8721 · DOI
  23. Garber, 2016, Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies, Neuro Oncol., 18, 1357, 10.1093/neuonc/now132 · DOI
  24. Goldberg, 2016, Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial, Lancet Oncol., 17, 976, 10.1016/S1470-2045(16)30053-5 · DOI
  25. Gustafson, 2010, Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasone, Neuro Oncol., 12, 631, 10.1093/neuonc/noq001 · DOI
  26. Hodges, 2017, Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy, Neuro Oncol., 19, 1047, 10.1093/neuonc/nox026 · DOI
  27. Hunter, 2006, A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy, Cancer Res., 66, 3987, 10.1158/0008-5472.CAN-06-0127 · DOI
  28. Ibrahim, 2015, PD-L1 blockade for cancer treatment: MEDI4736, Semin. Oncol., 42, 474, 10.1053/j.seminoncol.2015.02.007 · DOI
  29. Larkin, 2015, Combined nivolumab and ipilimumab or monotherapy in untreated melanoma, N. Engl. J. Med., 373, 23, 10.1056/NEJMoa1504030 · DOI · Paper page
  30. Le, 2015, PD-1 blockade in tumors with mismatch-repair deficiency, N. Engl. J. Med., 372, 2509, 10.1056/NEJMoa1500596 · DOI · Paper page
  31. Mirzaei, 2017, T cell exhaustion in glioblastoma: intricacies of immune checkpoints, Trends Immunol., 38, 104, 10.1016/j.it.2016.11.005 · DOI
  32. Miura, 2013, Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier, ACS Nano, 7, 8583, 10.1021/nn402662d · DOI
  33. Nduom, 2016, PD-L1 expression and prognostic impact in glioblastoma, Neuro Oncol., 18, 195, 10.1093/neuonc/nov172 · DOI
  34. Pardoll, 2012, The blockade of immune checkpoints in cancer immunotherapy, Nat. Rev. Cancer, 12, 252, 10.1038/nrc3239 · DOI · Paper page
  35. Powles, 2018, Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 391, 748, 10.1016/S0140-6736(17)33297-X · DOI · Paper page
  36. Quant, 2009, Role of a second chemotherapy in recurrent malignant glioma patients who progress on bevacizumab, Neuro Oncol., 11, 550, 10.1215/15228517-2009-006 · DOI
  37. Reardon, 2014, Immunotherapy advances for glioblastoma, Neuro Oncol., 16, 1441, 10.1093/neuonc/nou212 · DOI
  38. Reardon, 2016, Glioblastoma eradication following immune checkpoint blockade in an orthotopic, immunocompetent model, Cancer Immunol. Res., 4, 124, 10.1158/2326-6066.CIR-15-0151 · DOI · Paper page
  39. Reardon, 2016, Safety and activity of nivolumab (nivo) monotherapy and nivo in combination with ipilimumab (ipi) in recurrent glioblastoma (GBM): updated results from checkmate-143, JCO, 34
  40. Reardon, 2016, Results of the phase IB keynote-028 multi-cohort trial of pembrolizumab monotherapy in patients with recurrent PD-l1-positive glioblastoma multiforme (GBM), Neuro-Oncol., 10.1093/neuonc/now212.100 · DOI
  41. Reardon, 2017, OS10.3: randomized phase 3 study evaluating the efficacy and safety of nivolumab vs bevacizumab in patients with recurrent glioblastoma: CheckMate 143, Neuro Oncol., 19
  42. Reardon, 2017, Phase 2 study to evaluate safety and efficacy of MEDI4736 (durvalumab DUR]) in glioblastoma (GBM) patients: an update, JCO, 35
  43. Reardon, 2018, Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients, J. Clin. Oncol., 36, 10.1200/JCO.2018.36.15_suppl.2006 · DOI
  44. Reck, 2016, Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer, N. Engl. J. Med., 375, 1823, 10.1056/NEJMoa1606774 · DOI · Paper page
  45. Reiss, 2017, Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas, J. Immunother. Cancer, 5, 10.1186/s40425-017-0302-x · DOI
  46. Rittmeyer, 2017, Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial, Lancet, 389, 255, 10.1016/S0140-6736(16)32517-X · DOI
  47. Rizvi, 2015, Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer, Science, 348, 124, 10.1126/science.aaa1348 · DOI · Paper page
  48. Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2 · DOI · Paper page
  49. Schumacher, 2015, Biomarkers in cancer immunotherapy, Cancer Cell, 27, 12, 10.1016/j.ccell.2014.12.004 · DOI
  50. Schwartz, 2016, RECIST 1.1-update and clarification: from the RECIST committee, Eur. J. Cancer, 62, 132, 10.1016/j.ejca.2016.03.081 · DOI · Paper page
  51. Stewart, 2015, Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody, Cancer Immunol. Res., 3, 1052, 10.1158/2326-6066.CIR-14-0191 · DOI
  52. Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N. Engl. J. Med., 352, 987, 10.1056/NEJMoa043330 · DOI · Paper page
  53. Stupp, 2009, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, Lancet Oncol., 10, 459, 10.1016/S1470-2045(09)70025-7 · DOI
  54. Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690 · DOI · Paper page
  55. Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954 · DOI · Paper page
  56. Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol., 16, 375, 10.1016/S1470-2045(15)70076-8 · DOI
  57. Weller, 2013, Standards of care for treatment of recurrent glioblastoma--are we there yet?, Neuro Oncol., 15, 4, 10.1093/neuonc/nos273 · DOI
  58. Wintterle, 2003, Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis, Cancer Res., 63, 7462
  59. Yip, 2009, MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance, Clin. Cancer Res., 15, 4622, 10.1158/1078-0432.CCR-08-3012 · DOI
  60. Zaretsky, 2016, Mutations associated with acquired resistance to PD-1 blockade in melanoma, N. Engl. J. Med., 375, 819, 10.1056/NEJMoa1604958 · DOI · Paper page
  61. Zeng, 2013, Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas, Int. J. Radiat. Oncol. Biol. Phys., 86, 343, 10.1016/j.ijrobp.2012.12.025 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Caccese, M., Indraccolo, S., Zagonel, V., & Lombardi, G.
ORCID
Venue
Critical Reviews in Oncology/Hematology
Publisher
Elsevier BV
Published
2019-03
Volume
135
Pages
128-134
ISSN
1040-8428
DOI
10.1016/j.critrevonc.2018.12.002
Cited by
87
References
5
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review